Prosight Management’s Amedisys AMED Stock Holding History

Prosight Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$2.98M	–	39
2021 Q3	$2.98M	Buy	+20,000	New	+$4.16M	1.64%	22

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Prosight Management's AMED Position: Q4 2021 in Review

Prosight Management sold out of Amedisys (AMED) in Q4 2021, closing a stake of 20,000 shares — an estimated $2.98M sold.

Prosight Management first reported a position in AMED in Q3 2021 and held it in 1 quarter. The position peaked at $2.98M in Q3 2021. 324 funds tracked by Wall St. Rank hold AMED as of Q4 2021.

Prosight Management reported no remaining Amedisys position as of Q4 2021 after selling out during the quarter.
Prosight Management sold 20,000 Amedisys shares in Q4 2021, an estimated $2.98M.
Prosight Management first reported a position in Amedisys in Q3 2021 and held it in 1 quarter.
Prosight Management's Amedisys position peaked at $2.98M in Q3 2021.
324 funds tracked by Wall St. Rank held Amedisys as of Q4 2021.

Based on Prosight Management's 13F filing for Q4 2021, filed 14 Feb 2022.